Management of Hypertension in Patients with Chronic Kidney Disease and Cerebrovascular Accident

Primary Recommendation: ACE Inhibitor or ARB

The American Heart Association recommends that an ACE inhibitor (or ARB if ACE inhibitor is not tolerated) should be the first-line antihypertensive agent for a patient with prior cerebrovascular accident and CKD stage 3b, titrated to the maximum tolerated dose, with a target blood pressure <130/80 mmHg 1, 2, 3
ACE inhibitors or ARBs are mandatory first-line agents for all CKD patients with hypertension, particularly when albuminuria is present, according to the American College of Cardiology 1, 2, 3
For patients with CKD stage 3b, ACE inhibitors or ARBs should be administered at the highest approved dose that is tolerated, as clinical trial benefits were achieved at these target doses 2, 3
ARBs are reasonable alternatives if ACE inhibitors cause intolerable side effects, most commonly dry cough, as suggested by the American Heart Association 1, 4

The American Heart Association recommends a target blood pressure of <130/80 mmHg using standardized office measurement for patients with CKD and prior CVA 1, 2
The KDIGO guideline suggests an even lower target of systolic BP <120 mmHg when tolerated, though an acceptable alternative range is 130-139 mmHg systolic 2
The SPRINT trial demonstrated reduced cardiovascular events and all-cause mortality in CKD patients with intensive BP lowering (target <120 mmHg), though the primary kidney outcome showed no difference between intensive and standard therapy 1

The American College of Cardiology recommends checking serum creatinine and potassium within 2-4 weeks of initiating or increasing the dose of ACE inhibitors or ARBs 2, 3
Continue ACE inhibitor/ARB therapy unless serum creatinine rises by more than 30% within 4 weeks of initiation or dose increase, as suggested by the American Heart Association 1, 2, 3
An initial creatinine increase up to 30% is expected due to reduction in GFR from decreased intraglomerular pressure and should not prompt discontinuation unless accompanied by other concerning features 1

The American Diabetes Association recommends adding a long-acting dihydropyridine calcium channel blocker as second-line therapy when BP remains uncontrolled on ACE inhibitor or ARB monotherapy 5, 2
The American Journal of Kidney Diseases suggests adding a thiazide-type diuretic as third-line therapy for patients with eGFR ≥30 mL/min/1.73 m² 6, 2
For CKD stage 3b, thiazide diuretics remain effective and should not be automatically discontinued, though chlorthalidone is preferred over hydrochlorothiazide at this level of kidney function 6

The American Heart Association recommends never combining ACE inhibitor + ARB, as dual RAS inhibition increases risk of hyperkalemia, hypotension, and acute kidney injury without additional benefit 1, 6, 2, 4
The American Journal of Kidney Diseases suggests never using triple combination of ACE inhibitor + ARB + direct renin inhibitor, as this increases adverse events without benefit 2
Manage hyperkalemia associated with ACE inhibitor or ARB use through measures to reduce serum potassium rather than decreasing the dose or stopping the RAS inhibitor 2

The American Heart Association recommends incremental BP reduction with careful monitoring in patients with cerebrovascular disease, as they are at particular risk of hypotension-related complications 1
Avoid abrupt BP lowering that could compromise cerebral perfusion in patients with prior stroke and likely cerebrovascular disease 1